CRISPR Therapeutics AG (CRSP)
NASDAQ: CRSP · Real-Time Price · USD
56.88
-1.30 (-2.23%)
At close: Dec 5, 2025, 4:00 PM EST
57.17
+0.29 (0.52%)
After-hours: Dec 5, 2025, 7:59 PM EST
CRISPR Therapeutics AG Stock Forecast
Stock Price Forecast
According to 18 professional analysts, the 12-month price target for CRISPR Therapeutics AG stock ranges from a low of $32 to a high of $120. The average analyst price target of $71.5 forecasts a 25.70% increase in the stock price over the next year.
Price Target: $71.50 (+25.70%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for CRISPR Therapeutics AG stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 7 | 7 | 7 |
| Buy | 3 | 3 | 3 | 4 | 4 | 4 |
| Hold | 7 | 6 | 6 | 6 | 6 | 7 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 17 | 16 | 16 | 18 | 18 | 19 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $82 → $74 | Strong Buy | Maintains | $82 → $74 | +30.10% | Nov 26, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $87 → $77 | Strong Buy | Maintains | $87 → $77 | +35.37% | Nov 12, 2025 |
| RBC Capital | RBC Capital | Hold Maintains $42 → $50 | Hold | Maintains | $42 → $50 | -12.10% | Nov 11, 2025 |
| Baird | Baird | Hold Maintains $52 → $44 | Hold | Maintains | $52 → $44 | -22.64% | Nov 11, 2025 |
| Needham | Needham | Strong Buy Maintains $81 → $80 | Strong Buy | Maintains | $81 → $80 | +40.65% | Nov 10, 2025 |
Financial Forecast
Revenue This Year
15.58M
from 37.31M
Decreased by -58.24%
Revenue Next Year
128.37M
from 15.58M
Increased by 723.84%
EPS This Year
-6.32
from -4.34
EPS Next Year
-4.14
from -6.32
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 112.0M | 1.5B | ||||
| Avg | 15.6M | 128.4M | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 200.0% | 9,699.8% | ||||
| Avg | -58.2% | 723.8% | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -5.22 | 2.76 | ||||
| Avg | -6.32 | -4.14 | ||||
| Low | -6.72 | -6.77 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.